Riskpilot← Back to searchSign inGet full accessPHARMAMENTOR AS
ASActiveOrg 916006551Frydentoppveien 16, 4844 ArendalBusiness and other management consultancy activities · NACE 7020Est. 20150 employees
Revenue 2024
NOK 0
EBITDA margin
—
+35% vs 2023
Equity ratio
-2.6%
Financial strength
Net profit 2024
NOK -452K
-26% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -72K | +35% |
| Net profit | NOK -452K | -26% |
| Total assets | NOK 197K | -62% |
| Equity | NOK -5K | -101% |
| Employees | 0 | — |
Legal name
PHARMAMENTOR AS
Org number
916006551
Legal form
Aksjeselskap
NACE code
7020 · Business and other management consultancy activities
Founded
30. september 2015
Share capital
NOK 30 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Mentorvirksomhet og strategisk rådgivning innen legemiddelindustri, ledelse og kommunikasjon og annet som naturlig faller sammen med dette, herunder å delta i andre selskaper og lignende virksomheter, kjøp og salg av aksjer eller på andre måter gjøre seg interessert i andre foretagender.
Address
Frydentoppveien 16, 4844 Arendal
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42 | 636 | 1 261 | 1 775 | 1 494 | 1 386 | 769 | 0 | 0 | 0 |
| Staff expenses | −2 | −2 | −3 | −720 | −1 027 | −879 | −638 | −11 | −11 | −9 |
| EBITDA | −5 | 361 | 967 | 688 | 107 | 332 | −72 | −120 | −111 | −72 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −1 | −6 | −6 | −3 | −0 | −0 |
| EBIT | −5 | 361 | 967 | 688 | 106 | 326 | −78 | −123 | −111 | −72 |
| Net financials | 0 | 0 | 0 | −804 | 0 | 521 | −558 | 155 | −248 | −380 |
| Profit before tax | −5 | 361 | 967 | −116 | 106 | 847 | −636 | 32 | −358 | −452 |
| Tax | −2 | 90 | 232 | 170 | 35 | 53 | −2 | −0 | −0 | −0 |
| Net profit | −3 | 271 | 735 | −286 | 71 | 794 | −634 | 32 | −358 | −452 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 60 | 559 | 1 658 | 1 183 | 1 058 | 2 059 | 968 | 852 | 523 | 197 |
| Equity | 22 | 293 | 1 028 | 742 | 713 | 1 507 | 773 | 805 | 447 | −5 |
| Long-term debt | 0 | 0 | 0 | 0 | 1 | 185 | 114 | 46 | 0 | 0 |
| Short-term debt | 38 | 265 | 630 | 441 | 344 | 367 | 80 | 1 | 76 | 202 |
| Total debt | 38 | 265 | 630 | 441 | 344 | 552 | 195 | 47 | 76 | 202 |
EBITDA margin
-7195600.0%
This company
15.8%
Market median
-45541872% vs market
20152024
Equity ratio
-2.6%
This company
38.2%
Market median
-107% vs market
20152024
Return on equity
-45210600.0%
This company
18.4%
Market median
-245709883% vs market
20152024
Net profit margin
-45210600.0%
This company
8.1%
Market median
-558155656% vs market
20152024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152024
Debt / equity
38.77×
This company
0.62×
Market median
-6153% vs market
20152024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-09-07 – 2015-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2015 | — | — | |
| Board of Directors | 2015 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
PHARMAMENTOR AS 
INSULIFE ASBoard members of PHARMAMENTOR AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Åge Nærdal | Chairman | 0 companies |
| Thorunn Larsen Nærdal | Board of Directors | 0 companies |